On March 6, 2015 the North American Metal Packaging Alliance (NAMPA) commented on a recent study linking bisphenol A (BPA, CAS 80-05-7) exposure with autism (Stein et al. 2015, FPF reported). According to NAMPA, the findings of the study are suspect, as they fall far outside the established values set by comprehensive pharmacokinetics research on BPA metabolism. NAMPA argues that based on the published literature it is clear that humans metabolize more than 99% of ingested BPA. Data that show less than 99% metabolism, as in the case of the recent study, are a result of contaminated lab procedures, according to NAMPA. Low metabolism rates, as reported in the study, should have alerted researchers that they had a significant contamination issue. NAMPA is concerned that this issue was never raised during the peer review process. NAMPA compared the study design and other parameters against criteria established by the U.S. Food and Drug Administration (FDA) for pharmacokinetic studies and concluded that the study failed four out of the seven criteria.
NAMPA (March 6, 2015). “NAMPA Questions Validity of Study Connecting Bisphenol A (BPA) with Autism.” (pdf)
Stein, P. T. et al. (2015). “Bisphenol A exposure in children with autism spectrum disorders.”Autism Research (published online January 13, 2015).